Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is a world-wide medical aesthetics company, focused on delivering clinically validated solutions to support superior skin health and provider success. Despite guidance and estimate changes, SkinHealth has strong financial fundamentals with a projected revenue of $280mn-$295mn and an EBITDA of $35mn-$45mn in 2026, along with strong gross margins and operational efficiency. However, there is a potential risk associated with provider and brand reputation for Hydrafacial, as well as regulatory risk due to the company's products being subject to medical-device and cosmetic regulations. Despite this, SkinHealth has reported strong 4Q sales, with the Hydrafacial treatment remaining #1 in the microdermabrasion category and plans to innovate and launch a new system in 2028. The consumables business has also shown growth and the company continues to invest in science-backed boosters. However, there is competition in the global skincare, beauty, and aesthetics markets which could affect the company's ability to sustain brand awareness and develop new products.

Bears say

SkinHealth Systems is facing multiple headwinds, including declining consumable revenue, ongoing SEC investigations, and ongoing litigation. Additionally, the company relies heavily on its Hydrafacial platform, making it vulnerable to any negative events or a decline in demand for the product. With the potential impact of macroeconomic factors on consumer spending and the complex and costly regulatory process for its products, there are significant risks to the company's future performance.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.